A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Summary

To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.

Timeline

Start

2022-07-01

Primary completion

2024-06-21

Completion

2025-08-07

Outcome

Met primary endpoint

release “announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study (ClinicalTrials.gov, NCT05377580)” innoventbio.com ↗

Drugs

Indications